6/20/2019 8:19:48 AM
Alexion Pharma: FDA Accepts SBLA For ULTOMIRIS Under Priority Review For Atypical Hemolytic Uremic Syndrome
6/14/2019 6:34:59 AM
Alexion Pharma Says Positive Phase 3 Extension Data For ULTOMIRIS Presented At EHA Congress
4/25/2019 6:33:53 AM
Alexion Q1 GAAP EPS $2.61, Up 135% From Last Year
3/20/2019 7:07:42 AM
Alexion And Zealand Pharma Announce Collaboration To Develop Peptide Therapies For Complement-Mediated Diseases
3/20/2019 6:36:32 AM
Alexion And Affibody AB Announce Partnership To Co-develop ABY-039
2/4/2019 6:33:23 AM
Alexion Pharma Q4 Net Loss $45 Mln Or $0.20/shr Vs. Net Income $30.0 Mln Or $0.13/shr Last Year
1/31/2019 6:32:24 AM
Alexion And Caelum Biosciences Announce Collaboration To Develop Targeted Therapy For Light Chain Amyloidosis
1/31/2019 6:32:04 AM
Caelum Signs Strategic Agreement With Alexion To Advance Development Of CAEL-101 For Light Chain Amyloidosis
1/28/2019 6:31:58 AM
Alexion Pharma Says Phase 3 Study Of ULTOMIRIS Meets Its Primary Objective
11/2/2018 11:07:42 AM
Alexion Closes Acquisition Of Syntimmune